SCHEMBL1788152

SCHEMBL1788152

O=C(Cc1ccccc1)Nc1cccc(-c2nc3ccccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 17/20 0.81
EGFR P00533 9/20 0.81
KDR P35968 9/20 0.81
ERBB2 P04626 8/20 0.81
STK3 Q13188 8/20 0.81
MAP4K5 Q9Y4K4 8/20 0.81
RET P07949 7/20 0.81
FGFR1 P11362 6/20 0.81
TAOK1 Q7L7X3 6/20 0.81
LCK P06239 6/20 0.81
AURKB Q96GD4 6/20 0.81
MAP4K4 O95819 5/20 0.81
FYN P06241 5/20 0.81
MAP4K2 Q12851 5/20 0.81
AURKA O14965 4/20 0.81
PRKD3 O94806 4/20 0.81
INSR P06213 4/20 0.81
LYN P07948 4/20 0.81
FLT4 P35916 4/20 0.81
FRK P42685 4/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789377 0.91 IGF1R (0.68) IGF1REGFRKDRERBB2STK3
SCHEMBL1789032 0.91 IGF1R (0.67) IGF1REGFRKDRERBB2STK3
SCHEMBL1786668 0.91 IGF1R (0.67) IGF1REGFRKDRERBB2STK3
SCHEMBL1790090 0.91 IGF1R (0.67) IGF1REGFRKDRERBB2STK3
SCHEMBL1790140 0.90 IGF1R (0.72) IGF1REGFRKDRERBB2STK3
SCHEMBL1364343 0.89 IGF1R (1.00) IGF1REGFRKDRERBB2STK3
SCHEMBL1786852 0.86 IGF1R (0.80) IGF1REGFRKDRERBB2STK3
SCHEMBL1787369 0.86 IGF1R (0.80) IGF1REGFRKDRERBB2STK3
SCHEMBL1789944 0.86 BRAF (0.70) IGF1REGFRKDRERBB2STK3
SCHEMBL1785252 0.86 IGF1R (0.70) IGF1REGFRKDRERBB2STK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US claimed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 IGF1R 937/4885EGFR 1013/4885KDR 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.